Our study found that breast cancer with the HER2+ subtype (HR+/HER2+ and HR−/HER2+) is more prone to abdominal and pelvic metastases than the other BCS, and most of patients with abdominal and pelvic metastases were liver metastases. This evidence concerns the gene ERBB2 and breast carcinoma.